Biodegradable Cationic Lipids for Lower-Toxicity Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Therapeutic nucleic acids, such as siRNA and miRNA, face challenges of nuclease digestion in plasma and limited intracellular delivery when administered systemically, necessitating improved cationic lipids and lipid nanoparticles for protection and targeted delivery.
Innovation Solution
Development of cationic lipids with biodegradable groups incorporated into lipid particles for nucleic acid delivery, enhancing protection and intracellular delivery while reducing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cationic lipids without biodegradable groups are used for nucleic acid delivery, then the lipids provide stable structure and protection, but they accumulate in the body causing higher toxicity
Solution Approach 1:
The patent modifies the chemical structure of cationic lipids by introducing biodegradable groups (ester linkages) at specific positions in the lipid molecule. This parameter change allows the lipid to maintain structural integrity during delivery while enabling controlled degradation after delivering the nucleic acid, thereby reducing accumulation and toxicity.
Solution Approach 2:
The patent creates a dynamic lipid structure that transitions from a stable, protective state during delivery to a degradable state after delivery. The biodegradable groups allow the lipid to change its stability parameter based on the delivery phase, providing protection when needed and clearance when the payload is delivered.
2Object-affected harmful factors
If cationic lipids with biodegradable groups are used, then toxicity is reduced through faster metabolism, but the lipid structure becomes more susceptible to degradation
Solution Approach 1:
The patent introduces biodegradable groups at specific local positions within the lipid structure (e.g., at the omega position of fatty acid chains) rather than throughout the entire molecule. This localized degradation capability allows the rest of the lipid structure to remain stable and functional while providing controlled breakdown points for metabolism.
3Ease of operation
If conventional lipids are used for systemic delivery, then the nucleic acid can be delivered, but the lipids are not well-tolerated and show significant therapeutic index issues
Solution Approach 1:
The patent designs lipids that are intended to be transient in the body, performing their delivery function and then being rapidly metabolized and excreted. The biodegradable groups enable this short lifespan, preventing long-term accumulation and improving the therapeutic index by reducing chronic toxicity while maintaining effective delivery.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The biodegradable lipids provide faster metabolism and lower toxicity, ensuring effective delivery and therapeutic index of nucleic acids without significant patient risk.
Implementation Method 1
The biodegradable groups are located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic or PEG lipid. The incorporation of the biodegradable group(s) into the lipid results in faster metabolism and removal of the lipid from the body following delivery of the active agent to a target area.
Data Source
AI summary
The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.